RecoverLINK Technology Pilot for HF Patients

NCT ID: NCT02815085

Last Updated: 2018-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2018-06-30

Brief Summary

The primary objective is to examine feasibility of incorporating RecoverLINK into the standard of care as a function of (i) user engagement, (ii) user satisfaction, and (iii) workflow efficiency. As secondary objectives, the investigators will collect preliminary data to examine the association between patient engagement with the RecoverLINK app and (i) changes in patient knowledge and behavior, and (ii) hospital readmission(s) at 30, 60, and 90-day time periods post-enrollment.

Conditions

Heart Failure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

RecoverLINK technology

RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.

Group Type: EXPERIMENTAL

RecoverLINK technology

Intervention Type: OTHER

HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period

Interventions

RecoverLINK technology

HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Heart failure (HF) patients with a rapid follow up appointment scheduled at the Mount Sinai HF clinic
• English-speaking
• With either access to (i) an iOS smart device or (ii) wifi at-home

Exclusion Criteria

Patients meeting any of the following criteria:

• A heart transplant
• A mechanical circulatory support (MCS) device
• An altered mental status
• Serious co-morbidities (as identified by Mount Sinai team)
• Cognitive impairments (as identified by Mount Sinai team)
• Inability to use technology (as identified by Mount Sinai team)

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Mount Sinai Hospital, New York

OTHER

Sponsor Role: collaborator

Digital Health Marketplace (previously Pilot Health Tech NYC)

UNKNOWN

Sponsor Role: collaborator

RecoverLINK

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sean Pinney, MD

Role: PRINCIPAL_INVESTIGATOR

The Mount Sinai Hospital

Locations

The Mount Sinai Hospital

New York, New York, United States

Countries

United States

Other Identifiers

IF1793800

Identifier Type: -

Identifier Source: org_study_id